Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A
Autor: | Jeremy Rupon, Anna Plotka, Joan M. Korth-Bradley, Robert J Charnigo, Pablo Rendo |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
business.industry General Neuroscience General Medicine 030204 cardiovascular system & hematology Bioequivalence Gastroenterology Crossover study General Biochemistry Genetics and Molecular Biology Confidence interval Bioavailability 03 medical and health sciences 0302 clinical medicine Pharmacokinetics hemic and lymphatic diseases Internal medicine medicine Moroctocog alfa General Pharmacology Toxicology and Pharmaceutics business Adverse effect 030215 immunology Blood coagulation test |
Zdroj: | Clinical and Translational Science. 11:283-288 |
ISSN: | 1752-8054 |
DOI: | 10.1111/cts.12544 |
Popis: | An open-label, single-dose, randomized, two-period, crossover study comparing the pharmacokinetics of factor VIII activity in plasma (FVIII:C) after administration of an albumin-free presentation of moroctocog alfa (test) and moroctocog alfa manufactured using the previous technique (reference) was conducted in 30 (25 evaluable) male subjects who had severe hemophilia A (FVIII:C < 1 IU/dL). Blood samples were collected for 48 h after administration of each dose. FVIII C was assayed using a chromogenic substrate assay. The FVIII:C pharmacokinetic parameters were calculated using noncompartmental analysis. The presentations would be bioequivalent if the 90% confidence limits of the ratio of the geometric mean values of AUCinf and recovery fell within the interval of 80-125%. The bioequivalence criteria were met. A total of 10 treatment-related adverse events were observed in a total of nine subjects. All were mild and none was determined to be related to administration of study medication. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |